Denali Therapeutics

Historical price data

Denali Therapeutics is on a mission to defeat neurodegeneration by creating medicines that cross biological barriers, particularly the blood-brain barrier. Founded in 2015, the company has established its proprietary TransportVehicle™ (TV) platform as a core competitive moat, enabling the delivery of therapeutic antibodies, enzymes, and other biologics into the central nervous system. Its strategy leverages this platform to build a broad pipeline targeting diseases like Parkinson's, Alzheimer's, ALS, and lysosomal storage disorders, with key programs advancing through mid- to late-stage clinical trials. Denali has secured major partnerships with industry leaders like Biogen and Takeda, validating its approach and providing non-dilutive capital to fuel its ambitious R&D agenda.

The TransportVehicle™ (TV) platform is a proprietary blood-brain barrier delivery technology that uses engineered Fc fragments to hijack receptor-mediated transcytosis pathways, enabling the transport of large-molecule therapeutics like antibodies and enzymes into the central nervous system.

Denali is a leader in blood-brain barrier shuttle technology, competing with companies like Ikano (BMS) and ArmaGen. In disease areas, it faces large pharma in Alzheimer's/Parkinson's and established enzyme replacement therapy/gene therapy companies in lysosomal storage disorders. Its integrated platform and deep pipeline provide a differentiated position.